Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo

Concurrent targeting of BMI1 and CDK4/6 abrogates tumor growth in vitro and in vivo

<p dir="ltr">Despite recent advances in cancer management and therapy, resistance to cytotoxic medications remains a major clinical challenge; hence, combination-based anti-cancer treatment regimens are currently gaining momentum. PTC-209 reduced BMI1 protein expression, while palboc...

Full description

Saved in:
Bibliographic Details
Main Author: Ramesh Elango (7542068) (author)
Other Authors: Radhakrishnan Vishnubalaji (3563306) (author), Muthurangan Manikandan (6002243) (author), Sarah Ibrahim Binhamdan (18619234) (author), Abdul-Aziz Siyal (18619237) (author), Yasser A. Alshawakir (13730570) (author), Musaad Alfayez (3571736) (author), Abdullah Aldahmash (3563300) (author), Nehad M. Alajez (7397276) (author)
Published: 2019
Subjects:
Biomedical and clinical sciences
Oncology and carcinogenesis
Cancer management
Therapy resistance
Cytotoxic medications
Combination-based treatment regimens
PTC-209
Palbociclib
BMI1 protein expression
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items